Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Oral Finasteride for Severe Nodulocystic Acne
NCT02502669Phase 2Completed
- Sponsor
- Elorac, Inc.
- Start
- Jul 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of finasteride in nodulocystic acne (3 arms), sponsored by Elorac, Inc. Primary endpoint: Acne Nodular Lesion Count at 12 weeks. Started Jul 2015; status: completed.
02
Drugs
finasteride
03
Conditions
nodulocystic acne
Beyond the preview
Go deeper on NCT02502669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502669.